IRIS
MONTI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.586
AS - Asia 1.007
EU - Europa 906
SA - Sud America 144
AF - Africa 21
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.667
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.551
CN - Cina 407
IE - Irlanda 317
SG - Singapore 290
HK - Hong Kong 161
RU - Federazione Russa 151
DE - Germania 128
BR - Brasile 125
IT - Italia 75
FI - Finlandia 74
VN - Vietnam 50
GB - Regno Unito 34
SE - Svezia 26
AT - Austria 21
CA - Canada 20
ES - Italia 19
IN - India 18
ZA - Sudafrica 13
BD - Bangladesh 11
MX - Messico 11
PL - Polonia 10
TR - Turchia 10
NL - Olanda 9
BE - Belgio 8
ID - Indonesia 8
JP - Giappone 8
LT - Lituania 8
AR - Argentina 7
CZ - Repubblica Ceca 7
PK - Pakistan 6
SA - Arabia Saudita 6
EC - Ecuador 5
IQ - Iraq 5
UA - Ucraina 5
FR - Francia 4
UZ - Uzbekistan 4
DK - Danimarca 3
EG - Egitto 3
JO - Giordania 3
LK - Sri Lanka 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
AU - Australia 2
BH - Bahrain 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GD - Grenada 2
OM - Oman 2
PY - Paraguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
CH - Svizzera 1
CO - Colombia 1
GE - Georgia 1
GR - Grecia 1
IR - Iran 1
KE - Kenya 1
KG - Kirghizistan 1
KR - Corea 1
KZ - Kazakistan 1
LV - Lettonia 1
MA - Marocco 1
MM - Myanmar 1
NO - Norvegia 1
NP - Nepal 1
PE - Perù 1
SY - Repubblica araba siriana 1
UY - Uruguay 1
YT - Mayotte 1
Totale 3.667
Salva come PNG Salva come JPEG
Città #
Dublin 313
Chandler 309
Dallas 176
Hong Kong 161
Singapore 135
Ashburn 131
Beijing 122
New York 59
Boardman 55
Helsinki 55
Los Angeles 54
Munich 53
Princeton 51
Lawrence 46
Shanghai 42
Nanjing 34
Jacksonville 28
Medford 28
Wilmington 28
Chicago 25
Moscow 25
Ho Chi Minh City 20
Redondo Beach 19
Changsha 18
Nanchang 18
Vienna 18
Buffalo 17
Pavia 17
Seattle 15
Brooklyn 12
Falkenstein 12
São Paulo 12
Fairfield 11
Hanoi 11
Hebei 11
Milan 11
Turku 10
Hangzhou 9
Jiaxing 9
Toronto 9
Warsaw 9
Washington 9
Brussels 8
Johannesburg 8
London 8
Shenyang 8
Chennai 7
Phoenix 7
San Francisco 7
Santa Clara 7
Tokyo 7
Ankara 6
Columbus 6
Council Bluffs 6
Frankfurt am Main 6
Orem 6
Belo Horizonte 5
Boston 5
Brno 5
Denver 5
Jakarta 5
Manchester 5
Montreal 5
Norwalk 5
The Dalles 5
Tianjin 5
Albuquerque 4
Amsterdam 4
Atlanta 4
Berlin 4
Cagliari 4
Guangzhou 4
Poplar 4
Redwood City 4
Rio de Janeiro 4
Stockholm 4
Tashkent 4
Amman 3
Ann Arbor 3
Anápolis 3
Cape Town 3
Colombo 3
Genoa 3
Houston 3
Miami 3
Querétaro 3
Quito 3
San Jose 3
Turin 3
Woodbridge 3
Agawam 2
Borås 2
Brasília 2
Carpi 2
Catania 2
Chengdu 2
Chongqing 2
Cincinnati 2
Cleveland 2
Cuiabá 2
Totale 2.457
Salva come PNG Salva come JPEG
Nome #
20 years of experience with tumour necrosis factor inhibitors: what have we learned? 107
Cobalt hip prosthesis intoxication mimicking an autoimmune disease 107
Is it really infective endocarditis? Distinguishing systemic vasculitis from its mimics 106
The role of Trimethoprim/sulfametoxazole in reducing relapses and risk of infec-tions in ANCA-associated vasculitis: a meta-analysis 94
Aging in Primary Systemic Vasculitis: Implications for Diagnosis, Clinical Manifestations, and Management 92
Correspondence on 'EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs' 92
Cobalt hip prosthesis intoxication mimicking an autoimmune disease 91
Fast-Track Ultrasound Clinic for the Diagnosis of Giant Cell Arteritis Changes the Prognosis of the Disease but Not the Risk of Future Relapse 90
Impact of immunosuppressive treatment on the immunogenicity of mRNA Covid-19 vaccine in vulnerable patients with giant cell arteritis 88
The role of extra-corporeal membrane oxygenation (ECMO) in the treatment of diffuse alveolar haemorrhage secondary to ANCA-associated vasculitis: report of two cases and review of the literature 84
Cytomegalovirus colitis unmasking human immunodeficiency virus infection as a cause of IgA vasculitis 82
Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs 82
Anti-neutrophil cytoplasmic antibody specificity determines a different clinical subset in granulomatosis with polyangiitis 82
Chronic pain: The burden of disease and treatment innovations 80
Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors 80
Novel Therapies for ANCA-associated Vasculitis 80
Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis 79
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies 78
Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes 78
Lumbar spondylolisthesis associated with systemic sclerosis-related spinal calcinosis: an unusual clinical case 76
Safety of BNT162b2 mRNA COVID-19 vaccine in a cohort of elderly, immunocompromised patients with systemic vasculitis 75
Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients 73
Risk of acute arterial and venous thromboembolic events in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss syndrome) 73
Novel Diagnostic and Prognostic Approaches to Systemic Vasculitides 73
Clinical spectrum of anti-Jo-1-associated disease 71
Retention rate of IL-1 inhibitors in Schnitzler's syndrome 70
Spinal non-Hodgkin’s lymphoma mimicking a flare of disease in a patient with ankylosing spondylitis treated with anti-TNF agents: case report and review of the literature 68
Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak 68
Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis: a prospective analysis 67
Factors influencing patient-reported outcomes in ANCA-associated vasculitis: correlates of the Patient Global Assessment 66
Clinical course and outcome of COVID-19 in patients with rheumatic diseases: Are all biological disease-modifying antirheumatic drugs alike? Response to: Â € Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab' by Schulze-Koops et al 65
Blood biomarkers recommended for diagnosing and monitoring IgG4-related disease. Considerations from the ERN ReCONNET and collaborating partners 64
Switching from intravenous to subcutaneous formulation of abatacept: Different results in a series of 21 patients 63
Comorbidities and rheumatological diseases at the time of COVID-19. Response to: 'Rheumatic diseases in intensive care unit patients with COVID-19' by Moiseev et al 62
Rheumatoid arthritis treatment: the earlier the better to prevent joint damage 61
Early development of new cardiovascular risk factors in the systemic vasculitides 61
Azathioprine vs methotrexate in eosinophilic granulomatosis with polyangiitis: a monocentric retrospective study 61
Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? 56
Remission and Low-Disease Activity in Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Prevalence and Impact on Damage Accrual 54
Pneumocephalus due to granulomatosis with polyangiitis 54
Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: Ͽ Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and SLE, hydroxychloroquine and no SLE patients with COVID-19: A comment' by Joob and Wiwanitkit 54
Development and implementation of the AIDA International Registry for patients with Behçet’s disease 53
The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target?' by Capeechi et al 50
Striking abdominal aortic stenosis revealing Takayasu's arteritis 48
Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss) 48
Diagnostic and therapeutic challenges for patients with ANCA-associated vasculitides at the time of COVID-19. Response to: 'Rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: Lessons from a case with severe pneumonia' by Guilpain et al 47
Pneumocephalus due to granulomatosis with polyangiitis 46
Response to: 'Increased rather than decreased incidence of giant-cell arteritis during the COVID-19 pandemic' by Lecler et al 43
How I treat idiopathic patients with inflammatory myopathies in the clinical practice 41
Prevalence of COVID-19 among patients with rheumatic diseases: The need to await results from large collaborative studies. Response to: 'COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs' by Conticini et al 40
Validation of the Italian version of the ANCA-associated vasculitis patient-reported outcome (AAV-PRO) questionnaire 35
Derivation and validation of four patient clusters in Still's disease, results from GIRRCS AOSD-study group and AIDA Network Still Disease Registry 32
Humoral and T-cell immune response following three doses of SARS-CoV-2 mRNA vaccine in giant cell arteritis: analysis of a prospective cohort 30
Non-steroidal anti-inflammatory treatment during covid-19: Friend or foe? Response to: 'Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID)' by Giollo et al 30
Glucocorticoids versus glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis with poor-prognosis factors 29
Interstitial lung disease in microscopic polyangiitis and granulomatosis with polyangiitis: demographic, clinical, serological and radiological features of an Italian cohort from the Italian Society for Rheumatology 29
mRNA-COVID19 Vaccination Can Be Considered Safe and Tolerable for Frail Patients 26
Updates on the diagnosis and monitoring of giant cell arteritis 19
Efficacy of canakinumab in patients with Still’s disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still’s Disease 4
Totale 3.757
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.509
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.509
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202163 0 0 0 0 0 10 1 19 0 13 13 7
2021/2022203 4 1 13 2 4 14 1 11 9 6 27 111
2022/2023859 87 82 6 68 73 80 3 42 375 9 18 16
2023/2024396 63 75 18 16 30 83 25 32 3 20 15 16
2024/2025897 36 63 10 29 18 59 43 51 219 37 91 241
2025/20261.104 178 148 234 190 270 84 0 0 0 0 0 0
Totale 3.757